Trial Profile
A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 May 2020
Price :
$35
*
At a glance
- Drugs Necuparanib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms MAP1-A
- Sponsors Momenta Pharmaceuticals
- 28 Apr 2020 Primary endpoint (Part B: Overall Survival) has not been met.
- 28 Apr 2020 Results published in the European Journal of Cancer
- 21 Jan 2017 Results of an interim futility analysis for phase 2 (n=120, as of Jul 2016), presented at the 2017 Gastrointestinal Cancers Symposium.